SIROLIMUS | N213478 | NOBELPHARMA CO LTD
| Trial | Phase | Status | Sponsor | Enrollment | Dates |
|---|---|---|---|---|---|
| Phase 2 | Active | National Heart, Lung, and Blood Institute (NHLBI) | 84 | 2016-12-19 → 2030-06-30 | |
| Phase 2 | Active | City of Hope Medical Center | 72 | 2014-02-10 → 2026-09-21 | |
| Phase 2 | Active | Sarcoma Oncology Research Center, LLC | 31 | 2020-01-03 → 2028-03-31 | |
| N/A | Active | Biotronik AG | 116 | 2020-04-27 → 2027-02 | |
| Phase 2 | Active | National Heart, Lung, and Blood Institute (NHLBI) | 56 | 2014-04-21 → 2027-12-31 | |
| Phase 1/2 | Active | National Heart, Lung, and Blood Institute (NHLBI) | 57 | 2017-04-06 → 2026-08-31 | |
| Phase 2 | Active | National Cancer Institute (NCI) | 75 | 2004-10-28 → 2026-10-01 | |
| Phase 2 | Active | University of Pennsylvania | 7 | 2019-09-25 → 2027-06-30 | |
| N/A | Active | Biotronik AG | 1,861 | 2024-05-13 → 2032-02 | |
| Phase 3 | Active | CellTrans Inc. | 21 | 2007-09-05 → 2026-06-14 |
Source: ClinicalTrials.gov. Trials matched by ingredient name; data refreshed each weekday and may lag the registry.
Lowest Price
$1318.41
Highest Price
$1318.41
FSS NDCs
1
Big4 NDCs
0
| Description | Price | Type | Vendor | Contract End |
|---|---|---|---|---|
| 73683-0101-10HYFTOR 0.2% GEL,TOP | $1318.41 | FSS | Nobelpharma America, LLC | 05/14/2028 |
Source: VA Federal Supply Schedule (va.gov). Prices are government-negotiated contract prices.
Total Spending
$1.4M
Total Claims
375
Beneficiaries
81
Avg Cost/Unit
$183.60
Spending Trend
Source: CMS Medicare Part D Spending by Drug (2024). Shows gross drug cost under Part D.
15 active API suppliers hold Drug Master Files for this ingredient.
Source: FDA Drug Master Files (fda.gov). Type II API DMFs matched by ingredient.
| Date | Submission | Document |
|---|---|---|
| May 19, 2022 | ORIG -1 | View Letter (PDF) |
Source: Drugs@FDA application documents.
| Code | Date | Status |
|---|---|---|
| ODE-391 | Mar 22, 2029 | Active |